Candriam SCA’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-146,265
| Closed | -$8.98M | – | 711 |
|
|
2025
Q3 | $8.98M | Sell |
146,265
-2,330
| -2% | -$121K | 0.05% | 287 |
|
|
2025
Q2 | $7.26M | Sell |
148,595
-10,504
| -7% | -$499K | 0.04% | 298 |
|
|
2025
Q1 | $8.11M | Sell |
159,099
-1,010
| -0.6% | -$50.4K | 0.05% | 264 |
|
|
2024
Q4 | $7.23M | Sell |
160,109
-8,111
| -5% | -$347K | 0.04% | 305 |
|
|
2024
Q3 | $6.24M | Buy |
+168,220
| New | +$5.63M | 0.04% | 324 |
|
|
2024
Q2 | – | Sell |
-167,048
| Closed | -$4.86M | – | 715 |
|
|
2024
Q1 | $4.86M | Sell |
167,048
-124,604
| -43% | -$3.49M | 0.03% | 347 |
|
|
2023
Q4 | $8.04M | Hold |
291,652
| – | – | 0.06% | 281 |
|
|
2023
Q3 | $6.54M | Hold |
291,652
| – | – | 0.05% | 282 |
|
|
2023
Q2 | $11.9M | Buy |
291,652
+14,000
| +5% | +$685K | 0.09% | 223 |
|
|
2023
Q1 | $12.4M | Buy |
277,652
+75,000
| +37% | +$3.43M | 0.09% | 229 |
|
|
2022
Q4 | $7.73M | Hold |
202,652
| – | – | 0.05% | 315 |
|
|
2022
Q3 | $10.2M | Hold |
202,652
| – | – | 0.07% | 267 |
|
|
2022
Q2 | $8.12M | Sell |
202,652
-70,722
| -26% | -$2.48M | 0.07% | 257 |
|
|
2022
Q1 | $10.2M | Hold |
273,374
| – | – | 0.07% | 256 |
|
|
2021
Q4 | $10.9M | Hold |
273,374
| – | – | 0.07% | 252 |
|
|
2021
Q3 | $10.2M | Hold |
273,374
| – | – | 0.07% | 270 |
|
|
2021
Q2 | $11.6M | Sell |
273,374
-326,023
| -54% | -$14M | 0.08% | 269 |
|
|
2021
Q1 | $35.1M | Hold |
599,397
| – | – | 0.29% | 84 |
|
|
2020
Q4 | $36.6M | Sell |
599,397
-150,563
| -20% | -$8.87M | 0.29% | 84 |
|
|
2020
Q3 | $35.1M | Sell |
749,960
-24,000
| -3% | -$1.18M | 0.33% | 67 |
|
|
2020
Q2 | $39.3M | Buy |
773,960
+171,970
| +29% | +$8.45M | 0.41% | 51 |
|
|
2020
Q1 | $28.3M | Hold |
601,990
| – | – | 0.31% | 66 |
|
|
2019
Q4 | $28.9M | Sell |
601,990
-88,533
| -13% | -$3.76M | 0.31% | 66 |
|
|
2019
Q3 | $23.4M | Buy |
690,523
+50,000
| +8% | +$2.18M | 0.31% | 62 |
|
|
2019
Q2 | $28.7M | Buy |
640,523
+178,000
| +38% | +$7.03M | 0.36% | 56 |
|
|
2019
Q1 | $17.4M | Buy |
462,523
+60,000
| +15% | +$2.01M | 0.22% | 101 |
|
|
2018
Q4 | $13.8M | Buy |
402,523
+77,000
| +24% | +$2.77M | 0.21% | 111 |
|
|
2018
Q3 | $15.3M | Buy |
325,523
+169,523
| +109% | +$7.01M | 0.2% | 117 |
|
|
2018
Q2 | $5.26M | Buy |
156,000
+34,000
| +28% | +$1.06M | 0.08% | 287 |
|
|
2018
Q1 | $3.3M | Buy |
122,000
+35,000
| +40% | +$887K | 0.06% | 367 |
|
|
2017
Q4 | $1.45M | Buy |
87,000
+27,000
| +45% | +$457K | 0.03% | 515 |
|
|
2017
Q3 | $1.2M | Buy |
+60,000
| New | +$1.17M | 0.02% | 542 |
|
|
2016
Q1 | – | Sell |
-59,000
| Closed | -$1.91M | – | 649 |
|
|
2015
Q4 | $1.91M | Sell |
59,000
-15,000
| -20% | -$441K | 0.05% | 302 |
|
|
2015
Q3 | $1.98M | Buy |
74,000
+8,000
| +12% | +$342K | 0.05% | 344 |
|
|
2015
Q2 | $3.18M | Sell |
66,000
-31,000
| -32% | -$1.81M | 0.07% | 302 |
|
|
2015
Q1 | $5.9M | Sell |
97,000
-3,000
| -3% | -$183K | 0.12% | 229 |
|
|
2014
Q4 | $5.18M | Buy |
+100,000
| New | +$4.4M | 0.11% | 224 |
|
Other funds holding PTCT
RI
AC
Candriam SCA's PTCT Position: Q4 2025 in Review
Candriam SCA sold out of PTC Therapeutics (PTCT) in Q4 2025, closing a stake of 146,265 shares — an estimated $8.98M sold.
Candriam SCA first reported a position in PTCT in Q4 2014 and held it in 37 quarters. The position peaked at $39.3M in Q2 2020. 353 funds tracked by Wall St. Rank hold PTCT as of Q4 2025.
- Candriam SCA reported no remaining PTC Therapeutics position as of Q4 2025 after selling out during the quarter.
- Candriam SCA sold 146,265 PTC Therapeutics shares in Q4 2025, an estimated $8.98M.
- Candriam SCA first reported a position in PTC Therapeutics in Q4 2014 and held it in 37 quarters.
- Candriam SCA's PTC Therapeutics position peaked at $39.3M in Q2 2020.
- 353 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2025.
Based on Candriam SCA's 13F filing for Q4 2025, filed 13 Feb 2026.